

PROMOTION RECOMMENDATION
The University of Michigan
College of Pharmacy
Department of Clinical Pharmacy

Daniel L. Hertz, assistant professor of pharmacy, Department of Clinical Pharmacy, College of Pharmacy, is recommended for promotion to associate professor of pharmacy, with tenure, Department of Clinical Pharmacy, College of Pharmacy.

Academic Degrees:

Ph.D.	2013	University of North Carolina at Chapel Hill, Pharmaceutical Sciences
Pharm.D.	2008	Rutgers, The State University of New Jersey

Professional Record:

2016 – present	Assistant Professor, Department of Clinical Pharmacy, College of Pharmacy, University of Michigan
2013 – 2016	Research Assistant Professor, Department of Clinical Pharmacy, College of Pharmacy, University of Michigan

Summary of Evaluation:

Teaching: Professor Hertz is a very dedicated and prolific educator. He contributes to the undergraduate (BSPS), professional (PharmD), and graduate (PhD and MS) programs, as well as provides mentorship to post-doctoral fellows. He delivers a significant amount of didactic teaching, which speaks to his strong passion for educating students. It is clear from his teaching style that it is a priority for him to impart critical thinking skills to our students, which will aid their ongoing success. His use of contemporary case studies helps to give students context about complex therapeutic, scientific, and ethical issues. Professor Hertz is an innovative teacher who has taken leadership in revising long-standing courses in the PharmD curriculum by creating “real-world” scenarios. In addition to these didactic offerings, Professor Hertz has mentored two PhD students, six post-doctoral fellows, three BSPS students, and several PharmD students. He has provided mentorship to numerous PharmD students on their required research projects and capstone seminar presentations. His instructor ratings are very positive and consistently rank high in multiple domains. Professor Hertz’s quantity and quality of teaching and mentorship are exceptional.

Research: Professor Hertz’s research program is based in precision pharmacotherapy and focuses on improving cancer treatment outcomes by: 1) reducing the risk of chemotherapy-induced peripheral neuropathy (CIPN); 2) understanding how pharmacogenetics informs hormonal treatment of breast cancer; and 3) championing pre-treatment pharmacogenetic testing to reduce fluoropyrimidine toxicity, which is rare but can lead to death or disability in patients receiving fluoropyrimidine chemotherapy. His group recently prevented a major toxicity event in a patient by informing the oncologist of this risk days in advance of the planned dosing event, which highlights his impact as an outstanding pharmacist-scientist. Professor Hertz has been very successful obtaining funding for his work, which includes grants from the American Cancer Society and the National Institutes of Health. His scholarship productivity is exceptional for someone at the rank of assistant professor (90 papers, 78 as first or last author, h-index of 24). Professor Hertz has made 33 invited presentations, most of which were at the national level, which speaks to his reputation and recognition within his field of expertise.

Recent and Significant Publications:

- Hertz DL. Assessment of the Clinical Utility of Pretreatment *DPYD* Testing for Patients Receiving Fluoropyrimidine Chemotherapy. *J Clin Oncol*. 2022 Nov 20;40(33):3882-3892.
- Hertz DL, Chen L, Henry NL, Griggs JJ, Hayes DF, Derstine BA, Su GL, Wang SC, Pai MP. Muscle mass affects paclitaxel systemic exposure and may inform personalized paclitaxel dosing. *Br J Clin Pharmacol*. 2022 Jul;88(7):3222-3229.
- Hertz DL, McShane LM, Hayes DF. Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective. *J Clin Oncol*. 2022;24(10):02209.
- Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Lavoie Smith EM, Henry NL. Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. *Clin Cancer Res*. 2018 Aug 1;24(15):3602-3610.
- Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC. *CYP2C8*3* increases risk of neuropathy in breast cancer patients treated with paclitaxel. *Ann Oncol*. 2013 Jun;24(6):1472-8.

Service: Professor Hertz is an outstanding faculty citizen who consistently volunteers for student-facing activities and agrees to participate in or lead key strategic initiatives within the college. He currently serves as the College of Pharmacy representative to the U-M Faculty Senate and is a member of the U-M General Counsel Advisory Committee. Due to his prowess with clinical trial designs and leadership in the national Southwest Oncology Group (SWOG) Cancer Research Network, Professor Hertz, was appointed as a co-chair of the U-M Rogel Cancer Center's Cancer Control and Population Sciences Clinical Research Team. Beyond his broad college and U-M service, he makes substantial professional and scientific service contributions. He has had leadership roles in the *American Society of Clinical Pharmacology and Therapeutics*, *Pharmacogenomics Research Network*, *Enhancing Pharmacogenomics in Oncology Organization*, *Standardizing Laboratory Practices in Pharmacogenomics*, and other pharmacy-related organizations. He is a sought-after manuscript and grant reviewer. He is a very active advocate for pre-treatment testing prior to fluoropyrimidine treatment and serves on the Medical Advisory Board. This advocacy effort has led to a Citizen's Petition of the US FDA to consider mandating this test. He is also involved with Camp Kesem, which seeks to improve the well-being of children who have or had parents with cancer. Professor Hertz's record of service to the academy and to scientific and professional organizations is exceptional.

External Reviewers:

Reviewer A: "Dr. Hertz has made significant research, scholarly, teaching, and service contributions...This repeated success in large grant funding shows the impact and quality of his research and a trajectory for ongoing success...He is a nationally-recognized and respected leader within pharmacy and the oncology space...he made impactful service commitments to key organizations within clinical cancer research (e.g. SWOG) and for cancer patients...I expect Dr. Hertz's advocacy for PGx (DPYD) testing will be impactful on the field and will lead to practice change."


Reviewer B: “Dr. Hertz has excelled in his academic pursuits...His number of publications, 2318 citations and h-index of 25 are very impressive...His manuscripts, along with his recent focus on implementation science and *DPYD* testing, have moved the field forward in adoption of genomic testing for patient care...Dr. Hertz has contributed substantially to educating the next generation of pharmacy professionals, as well as peers and others...his passion for training and mentoring comes through clearly in his work....”

Reviewer C: “...I would consider his research contributions to be excellent to outstanding... Dr. Hertz has also made substantial contributions to graduate curriculum,...which is impressive given his research productivity...Based on the extent of his involvement and leadership in national and interprofessional organizations, I would consider his service to be outstanding in terms of quality and quantity...There is no question in my mind that Dr. Hertz would meet the requirements for promotion to Associate Professor with tenure at [my institution].”

Reviewer D: “...I have been well aware of his stellar work and high impact publications... Dr. Hertz has an extremely productive research program focused on advancement of personalized treatment tools for improving cancer care...Dr. Hertz’s scholarly record is reflective of a seasoned academic with a very bright future who attracts and supports numerous students and impacts the research which holds potential to improve clinical practice in cancer patients.”

Reviewer E: “Dr. Hertz’[s] scientific contribution is outstanding both in terms of the overall quality, and the general relevance and applicability...Dr. Hertz’[s] excellent scholarly accomplishments over the years have majorly contributed to subsequent directions taken in the onco-toxicology field and are testament to his impressive career as a scientific opinion leader...I regard Dr. Hertz as an extraordinarily talented researcher, who has already made significant contributions to his various areas of expertise.”

Summary of Recommendation: Professor Hertz is an outstanding scientist and extremely dedicated teacher, mentor, and citizen who is making a difference in the treatment of cancer through his research and its application to patient care, as well as through his training of future clinicians and scientists and service to his profession. It is with great pleasure that I recommend Daniel L. Hertz for promotion to associate professor of pharmacy, with tenure, Department of Clinical Pharmacy, College of Pharmacy.



Vicki L. Ellingrod, PharmD, FCCP, FACNP
Dean
John Gideon Searle Professor, Professor of
Pharmacy
Professor of Psychiatry
College of Pharmacy

May 2023